Fundraising FoxG1 Therapeutics
Research Triangle Park, US · Delaware corporation · 5 known investors
Find your way into G1 Therapeutics
Sign up to see every warm intro you have to G1 Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the G1 Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
Founders & leadership
Board
Investors · 5
How we know: Lumira Ventures's portfolio page · Not right? Tell us
How we know: Mountain Group Capital's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$79.1M disclosed across 3 rounds · 2013–2016
▶$50MraisedJul 2016 · 21 investors · BiotechnologyRule 506(b)
- Timothy SullivanDirector
- Peter KolchinskyDirector
- Mark A. VellecaExecutive Officer, Director
- Glenn MuirDirector
- Gregory MossinghoffExecutive Officer
- Seth RudnickDirector
- Ron LauferDirector
- Frederic N. EshelmanDirector
- Christy ShafferDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.5MraisedFeb 2015 · 10 investors · BiotechnologyRule 506(b)
- Ron LauferDirector
- Christy ShafferDirector
- Seth RudnickDirector
- Carol WebbDirector
- Clay ThorpDirector
- Michael GutchDirector
- Mark A. VellecaExecutive Officer, Director
- Norman SharplessDirector
- Gregory MossinghoffExecutive Officer
- Offering amount
- $33M
- Amount sold
- $16.5M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.6MraisedJun 2014 · 8 investors · BiotechnologyRule 506(b)
- Ron LauferDirector
- Michael GutchDirector
- Thomas K LaundonExecutive Officer
- Carol WebbDirector
- Jay StrumExecutive Officer
- Christy ShafferDirector
- Mark A. VellecaExecutive Officer, Director
- Norman SharplessDirector
- Seth RudnickDirector
- Offering amount
- $12.6M
- Amount sold
- $12.6M
- First sale
- Oct 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through G1 Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does G1 Therapeutics do?
- G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
- Who founded G1 Therapeutics?
- G1 Therapeutics was founded by Jay Strum, Norman Sharpless.
- Who are G1 Therapeutics's investors?
- G1 Therapeutics's investors include Lumira Ventures, Mountain Group Capital, RA Capital, Solasta Ventures, Hatteras Venture Partners.
- How much funding has G1 Therapeutics raised?
- G1 Therapeutics has disclosed $79.1M raised across 3 rounds.
- Where is G1 Therapeutics headquartered?
- G1 Therapeutics is headquartered in Research Triangle Park, US.